Physician profile
Afreeda Hashmi
NPI 1386085942
$979.38
in general payments reported to CMS, 2019-2025
16 companies · $48.15 in 2025
The $48.15 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $78.38 · 2022: $18.95 · 2023: $419 · 2024: $98.59 · 2025: $48.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.97 | 2023-2025 | |
| Novo Nordisk INC | $151.06 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $79.67 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $72.79 | 2019-2023 | Breztri |
| Pfizer INC. | $69.78 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $66.86 | 2019-2020 | |
| Astellas Pharma US INC | $52.69 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $46.22 | 2019 | |
| Exact Sciences Corporation | $37.16 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $33.38 | 2023-2024 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $30.96 | 2019 | |
| Glaxosmithkline, LLC. | $24.95 | 2023 | Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2019 | |
| Lilly USA, LLC | $19.99 | 2023 | Jardiance |
| Amarin Pharma, INC. | $16.23 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afreeda Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.